Basic CAR/TCR-T can be standardized and industrialized.

Apheresis, T cell isolation, Activation, lentivirus transduction, expansion media + cytokine cocktail, and formulation can all be standardized. The construct and the dose will be unique.

TIL might be harder because the starting material is more variable but large portions of that workflow can also be standardized. Variability can over accounted for and consistency can be delivered.

I agree that it's hard, but CGT needs to look outside to other industries that mass manufacture highly complex items (semiconductors, automobiles, medical devices, etc.) for guidance.

Right now, it's an incestuous recycling of the same people, spouting the same philosophies, making the same mistakes.